29 July 2013
UCL scientists have carried out the first successful transplant of light-sensitive photoreceptor cells extracted from a synthetic retina, grown ‘in a dish’ from embryonic stem cells.
When transplanted into night-blind mice these cells appeared to develop normally, integrating into the existing retina and forming the nerve connections needed to transmit visual information to the brain.
The study, funded by the Medical Research Council (MRC) and published today in Nature Biotechnology, suggests that embryonic stem cells could in future provide a potentially unlimited supply of healthy photoreceptors for retinal cell transplantations to treat blindness in humans.
The loss of photoreceptors – light sensitive nerve cells that line the back of the eye – is a leading cause of sight loss in degenerative eye diseases such as age-related macular degeneration, retinitis pigmentosa and diabetes-related blindness.
There are two types of photoreceptor in the eye – rods and cones. Rod cells are especially important for seeing in the dark as they are extremely sensitive to even low levels of light.
Previous work by Professor Robin Ali and his team at the UCL Institute of Ophthalmology and Moorfields Eye Hospital has shown that transplanting immature rod cells from the retinas of healthy mice into blind mice can restore their sight. However, in humans this type of therapy would not be practical for the thousands of patients in need of treatment.
Using a new laboratory technique involving 3D culture and differentiation of mouse embryonic stem cells, which was developed recently in Japan, Prof Ali’s team were able to grow retinas containing all the different nerve cells needed for sight.
Professor Ali, UCL Institute of Ophthalmology and Moorfields Eye Hospital, who led the research, said: “Over recent years scientists have become pretty good at working with stem cells and coaxing them to develop into different types of adult cells and tissues. But until recently the complex structure of the retina has proved difficult to reproduce in the lab. This is probably because the type of cell culture we were using was not able to recreate the developmental process that would happen in a normal embryo.
“The new 3D technique more closely mimics normal development, which means we are able to pick out and purify the cells at precisely the right stage to ensure successful transplantation. The next step will be to refine this technique using human cells to enable us to start clinical trials.”
The researchers grew retinal precursor cells using the new 3D culture method and compared them closely with cells developed normally, looking for different markers at different stages of development. They also carried out tests to look at the genes being expressed by the two types of cells to make sure they were biologically equivalent.
They then transplanted around 200,000 of the artificially grown cells by injecting them into the retina of night blind mice. Three weeks after transplantation the cells had moved and integrated into the recipient mouse retina and were beginning to look like normal mature rod cells. These cells were still present six weeks after transplantation. The researchers also saw nerve connections (synapses), suggesting that the transplanted cells were able to connect with the existing retinal circuitry.
Dr Rob Buckle, Head of Regenerative Medicine at the MRC, said: “Regenerative medicine holds a great deal of promise for treating degenerative diseases and the eye is one area in particular where scientists are making very rapid progress. This study is an important milestone on the road to developing a widely available cell therapy for blindness as it proves unequivocally that embryonic stem cells can provide a renewable source of photoreceptors that could be used in treatments.”
UCLB will be working with Robin in translating this into a therapy for humans.
For more information please contact Dr Rachel Hemsley T: 020 7679 9000 E: firstname.lastname@example.org
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.
UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit: www.uclb.com